Overall rank by patents
#47,628
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A42B (HATS; Head Coverings).
The verdict
According to USPTO PatentsView, Impact ranks #47,628 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.
USPTO PatentsView assignee plate
Corpus R47628 · US Corporation #47,628 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: ImmunGene Inc (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Impact Solutions · this assignee
32 score
3D Lighting… · lowest
7 score
What this shows Impact's Innovation Score is 32.2/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Impact Solutions is a focused PatentsView assignee: 6 CPC subclasses with 60% of grants classified under A42B (HATS; Head Coverings). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2022. By volume, Impact sits between ImmunGene Inc and Inception Innovations, Inc..
Impact Solutions shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ImmunGene Inc
5 patents
ImmunoMolecular Therapeutics, Inc.
5 patents
Immunology Laboratories, Inc.
5 patents
Immy Inc.
5 patents
In The Black Revocable Trust
5 patents
InTunes Products, LLC
5 patents
Incanthera Ltd
5 patents
Inception Innovations, Inc.
5 patents
Impact Solutions
5 patents
What this shows Impact holds 5 patents at rank #47,767, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #47,767 in granted patent volume.
Other assignees with the most granted patents in Impact's primary technology class.
Impact's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
32 40th percentile higher than 40% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 2 | 40.0% |
| 2022 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
| 2025partial year | 1 | 20.0% |
Top 6 of 6 technology areas
Overall rank by patents
#47,628
of 49,997 tracked assignees
32.2 out of 100
What to do with this data
Impact Solutions's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.